Accendra Health Extends $150M Receivables Purchase Agreement To October 2029 With Its Size Unchanged

 The amendment, among other things, extends the Scheduled Termination Date of the facility to October 2029, and the $150 million size of the Receivables Sale Program is unchanged.

"We are pleased to have worked with our banking partner to extend the Receivables Sale Program until October of 2029. The facility size remains unchanged, further ensuring the Company’s liquidity strength, and we believe that this continued partnership demonstrates the strength of our accounts receivable portfolio and processes," said Jonathan Leon, EVP and Chief Financial Officer of Accendra Health, Inc.